Nanomaterials incorporated ultrasound contrast agents for cancer theranostics

• Published in: Cancer biology & medicine Vol. 13; no. 3; pp. 313 - 324
• Main Authors: Fu, Lei, Ke, Heng-Te
• Format: Journal Article
• Language: English
• Published: China College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China%Center of Systems Medicine, Chinese Academy of Medical Sciences, Suzhou Institute of Systems Medicine, Suzhou 215123, China 01.09.2016; Chinese Anti-Cancer Association; China Anti-Cancer Association
• Subjects: Cancer; nanomaterials; nanomedicine; Review; theranostics; ultrasound contrast agents; nanomedicine; theranostics; cancer; nanomaterials; ultrasound contrast agents; Cancer
• ISSN: 2095-3941; 2095-3941
• DOI: 10.20892/j.issn.2095-3941.2016.0065

Nanotechnology provides various nanomaterials with tremendous functionalities for cancer diagnostics and therapeutics.Recently, theranostics has been developed as an alternative strategy for efficient cancer treatment through combination of imaging diagnosis and therapeutic interventions under the guidance of diagnostic results. Ultrasound（US） imaging shows unique advantages with excellent features of real-time imaging, low cost, high safety and portability, making US contrast agents（UCAs）an ideal platform for construction of cancer theranostic agents. This review focuses on the development of nanomaterials incorporated multifunctional UCAs serving as theranostic agents for cancer diagnostics and therapeutics, via conjugation of superparamagnetic iron oxide nanoparticles（SPIOs）, Cu S nanoparticles, DNA, si RNA, gold nanoparticles（GNPs）, gold nanorods（GNRs）, gold nanoshell（GNS）, graphene oxides（GOs）, polypyrrole（PPy） nanocapsules, Prussian blue（PB） nanoparticles and so on to different types of UCAs. The cancer treatment could be more effectively and accurately carried out under the guidance and monitoring with the help of the achieved theranostic agents. Furthermore, nanomaterials incorporated theranostic agents based on UCAs can be designed and constructed by demand for personalized and accurate treatment of cancer, demonstrating their great potential to address the challenges of cancer heterogeneity and adaptation, which can provide alternative strategies for cancer diagnosis and therapeutics.